Is an anti‑Treponema pallidum test the same as a rapid plasma reagin (RPR) or venereal disease research laboratory (VDRL) test?

No, Anti-Treponema pallidum Tests Are NOT the Same as RPR or VDRL

Anti-Treponema pallidum tests and nontreponemal tests (RPR/VDRL) are fundamentally different types of serologic assays that detect distinct antibodies and serve different clinical purposes in syphilis diagnosis.

Key Differences Between Test Types

Nontreponemal Tests (RPR/VDRL)

• Detect antiphospholipid antibodies (not specific to T. pallidum)—these are host antibodies made in response to phosphatidylcholine taken up from mammalian tissue by the bacterium 1
• Non-specific: Can be positive in conditions other than syphilis
• Quantitative titers are used to monitor treatment response 1
• Examples: Rapid Plasma Reagin (RPR), Venereal Disease Research Laboratory (VDRL), TRUST 1

Treponemal Tests (Anti-Treponema pallidum)

• Detect antibodies specific to T. pallidum antigens 1, 2
• Highly specific for treponemal infection
• Examples: TPPA (T. pallidum particle agglutination), FTA-ABS (fluorescent treponemal antibody absorption), MHA-TP, and treponemal EIA/CIA (enzyme/chemiluminescence immunoassays) 3, 4
• Generally remain positive for life, even after successful treatment 2

Clinical Implications: Why Both Tests Are Needed

Both test types must be used in conjunction to distinguish between untreated infection and past treated infection 5. This is critical because:

• Treponemal tests alone cannot differentiate active from past infection
• Nontreponemal tests provide quantitative titers that decline with successful treatment 1
• Using only one test type leads to diagnostic errors

Testing Algorithms

Traditional Algorithm (still CDC-recommended):

1. Screen with nontreponemal test (RPR/VDRL)
2. Confirm reactive results with treponemal test 4, 5

Reverse Sequence Algorithm (increasingly common due to automation):

1. Screen with treponemal EIA/CIA
2. Confirm reactive results with nontreponemal test (RPR/VDRL)
3. If discordant (treponemal positive, nontreponemal negative), perform second treponemal test (TPPA or FTA-ABS) 3, 4, 5

Performance Characteristics

Recent comparative studies demonstrate the superior performance of treponemal tests:

• ELISA (treponemal): 98% sensitivity, 97.5% specificity 6
• RPR: 73.5% sensitivity, 90.5% specificity 6
• VDRL: 71.6% sensitivity, 89.5% specificity 6

ELISA showed excellent agreement (kappa=0.9) with TPHA compared to VDRL/RPR which had only moderate agreement (kappa=0.6) 6.

Common Pitfalls to Avoid

False-Positive Nontreponemal Tests

RPR/VDRL can be falsely positive in:

• Pregnancy
• Autoimmune diseases
• HIV infection
• Malaria
• Recent vaccinations 1

False positivity rates: VDRL 10.5%, RPR 9.6%, versus ELISA 2.5% 6

Reverse Sequence Screening Issues

Among sera reactive on treponemal EIA/CIA screening, 56.7% had nonreactive RPR, and among these discordant results, 31.6% were also nonreactive by confirmatory treponemal testing (TPPA/FTA-ABS)—representing false-positives 4. The false-positive rate was 2.9 times higher in low-prevalence populations 4.

Neurosyphilis Diagnosis

For CSF testing, only CSF-VDRL should be used (not serum RPR/VDRL) 7, 8. CSF treponemal tests have high sensitivity but lower specificity than CSF-VDRL 7. However, inappropriate CSF-VDRL testing remains problematic—in one study, 98.2% of negative CSF-VDRL tests were inappropriately ordered 8.

Bottom Line for Clinical Practice

You cannot substitute one test for the other—they measure different antibodies and provide complementary diagnostic information. The treponemal test confirms T. pallidum infection, while the nontreponemal test (RPR/VDRL) helps determine disease activity and treatment response 1, 2, 5.